立方制药（003020）8月8日主力资金净流出3219.22万元

Company Performance - As of August 8, 2025, Lifan Pharmaceutical (stock code 003020) closed at 27.1 yuan, down 0.88%, with a turnover rate of 5.63% and a trading volume of 77,600 lots, amounting to 211 million yuan [1] - The latest quarterly report shows total revenue of 360 million yuan, a year-on-year increase of 7.98%, and a net profit attributable to shareholders of 38.25 million yuan, up 25.94% year-on-year [1] - The company's non-recurring net profit was 31.60 million yuan, reflecting an 11.28% year-on-year growth [1] - Financial ratios include a current ratio of 2.142, a quick ratio of 1.723, and a debt-to-asset ratio of 24.82% [1] Capital Flow - On the reporting day, the net outflow of main funds was 32.19 million yuan, accounting for 15.24% of the total transaction amount [1] - Large orders saw a net outflow of 27.09 million yuan, representing 12.82% of the transaction amount, while small orders had a net inflow of 40.26 million yuan, making up 19.06% of the transaction amount [1] Company Background - Hefei Lifan Pharmaceutical Co., Ltd. was established in 2002 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.9018 billion yuan and a paid-in capital of 660 million yuan [1] - The company has made investments in 11 enterprises and has participated in 5,000 bidding projects [2]